FRNM Stock — Freenome, Inc. Common stock

Freenome, Inc. Common stock (FRNM)

Updated October 16, 2026.

FRNM is a Stock. Total return is 4.9% over the past 0.3 years, 2.7 points ahead of SPY at 2.2%.

Freenome, Inc. is a biotechnology company that develops blood-based screening tests designed to detect cancer early using multiomics, artificial intelligence, and machine learning. The company's platform includes SimpleScreen CRC for colorectal cancer screening and tests in development for other cancers including lung, breast, cervical, liver, pancreatic, and esophageal cancers. This stock does not currently distribute dividends and appeals primarily to investors seeking exposure to early-stage cancer diagnostics innovation rather than current income.

FRNM performance versus SPY

Price and return data through 2026-10-16.

Total return is 4.9% over the past 0.3 years, 2.7 points ahead of SPY at 2.2%.

FRNM key facts

Asset type

Stock

Asset class

Equity

Inception date

06/16/2026

Distribution frequency

None

Last close

$11.75 (as of 2026-10-16)

Market cap

$1,262,500,064

Average volume

902987.0

Beta

0.445

Payout ratio

0.0%

EPS

$-2.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider FRNM — and who may not

It is a weaker fit for investors who need monthly cash flow (FRNM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on FRNM

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions